PRIMA RECEIVES US PATENT GRANT FOR CVAC
Great news. Cheap down here.
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (Prima, the Company)
announces that the US patent number 8,771,701 titled Compositions for immunotherapy and
uses thereof, which protects the Companys CVac technology, has been granted by the
United States Patent and Trademark Office (USPTO).
Prima has also received a patent term adjustment of 1,409 days for US 8,771,701, extending the
patent expiry date for the US market to August 2022.
Chief Executive Officer of Prima, Mr Marc Voigt said: The grant of this key US patent with a
patent term adjustment of almost four years is an important value proposition for Prima. The
patent term can potentially be further extended by up to five years if CVac receives market
approval before it expires, which would provide the Company with essential protection over its
commercial development well into the future. :lol: :cool:
I was beggining to think I was the only one following this stock. It is starting to look cheap, either as a growth stock or a takeover with a juicy patent on a fast track drug. :lol: